secwatch.observer — SEC 8-K summary
======================================

Issuer:     DELCATH SYSTEMS, INC. (DCTH)
CIK:        0000872912
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0001628280-24-012996
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Delcath Systems reports Q4/FY2023 results; first HEPZATO KIT use, site guidance raised to 20
--------------------------------------------------------------------------------

- First commercial HEPZATO KIT treatment for metastatic uveal melanoma performed at Moffitt Cancer Center.
- Increased 2024 active treatment site guidance from 15 to 20 sites; three sites activated, four more imminent.
- Product-specific J-code (J9248) and transitional pass-through payment effective April 1, 2024, from CMS.
- Appointed Dr. Martha S. Rook as COO; raised $7.0M in private placement from insiders and existing investors.
- Cash $32.5M at Dec 31, 2023; FY2023 revenue $2.1M (down from $2.7M); SG&A increased to $22.1M for commercial prep.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872912/000162828024012996/0001628280-24-012996-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872912/000162828024012996/dcth-20240326.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-012996

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer